Tony Yu's most recent trade in Genelux Corp was a trade of 906 Common Stock done at an average price of $2.4 . Disclosure was reported to the exchange on March 24, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Genelux Corp | Tony Yu | SVP, Clinical Development | Sale of securities on an exchange or to another person at price $ 2.42 per share. | 24 Mar 2026 | 906 | 144,938 | - | 2.4 | 2,193 | Common Stock |
| Genelux Corp | Tony Yu | SVP, Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2025 | 207,652 | 0 | - | - | Stock Option (Right to Buy) | |
| Genelux Corp | Tony Yu | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 207,652 | 207,652 | - | - | Stock Option (Right to Buy) | |
| Genelux Corp | Tony Yu | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Genelux Corp | Tony Yu | SVP, Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Sep 2025 | 65,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Genelux Corp | Tony Yu | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2025 | 134,520 | 134,520 | - | - | Stock Option (Right to Buy) | |
| Genelux Corp | Tony Yu | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2025 | 101,480 | 150,036 | - | 0 | Common Stock | |
| Genelux Corp | Tony Yu | SVP, Clinical Development | Sale of securities on an exchange or to another person at price $ 3.36 per share. | 21 Aug 2025 | 3,219 | 146,817 | - | 3.4 | 10,807 | Common Stock |
| Genelux Corp | Tony Yu | SVP, Clinical Development | Sale of securities on an exchange or to another person at price $ 5.37 per share. | 21 Aug 2025 | 973 | 145,844 | - | 5.4 | 5,224 | Common Stock |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 2.92 per share. | 12 May 2025 | 5,579 | 47,640 | - | 2.9 | 16,291 | Common Stock |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 13,350 | 53,219 | - | 0 | Common Stock | |
| Genelux Corp | Yu Tony | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 39,000 | 39,000 | - | - | Stock Option (right to buy) | |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 29,000 | 39,869 | - | 0 | Common Stock | |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 2,500 | 2,500 | - | - | Common Stock Warrant (Right to Buy) | |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 2,500 | 2,500 | - | - | Common Stock | |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 11,557 | 17,718 | - | 0 | Common Stock | |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 2.12 per share. | 19 Feb 2024 | 6,849 | 10,869 | - | 2.1 | 14,520 | Common Stock |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 3,661 | 6,161 | - | 0 | Common Stock | |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 15 Dec 2023 | 26,732 | 5,803 | - | 12.9 | 345,915 | Common Stock |
| Genelux Corp | Yu Tony | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 14.18 per share. | 15 Dec 2023 | 5,803 | 0 | - | 14.2 | 82,265 | Common Stock |
| Genelux Corp | Yu Tony | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 11.85 per share. | 07 Dec 2023 | 36,800 | 32,535 | - | 11.8 | 435,995 | Common Stock |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 24.70 per share. | 30 Aug 2023 | 19,800 | 135,935 | - | 24.7 | 489,060 | Common Stock |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 23.73 per share. | 18 Aug 2023 | 3,265 | 155,735 | - | 23.7 | 77,478 | Common Stock |
| Genelux Corp | Tony Yu | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 9,000 | 159,000 | - | 0 | Common Stock |